Global Information
회사소개 | 문의 | 위시리스트

대사 의약품 시장 : 규모, 점유율, 동향, 예측(-2026년)

Metabolism Drugs Market - Size, Share, Trends, and Forecast till 2026

리서치사 Coherent Market Insights
발행일 2018년 07월 상품 코드 785767
페이지 정보 영문
가격
US $ 4,500 ₩ 5,497,000 PPT Turned PDF (Single User License)
US $ 7,000 ₩ 8,551,000 PPT Turned PDF (Multi-user License)
US $ 10,000 ₩ 12,217,000 PPT Turned PDF (Enterprise User License)


대사 의약품 시장 : 규모, 점유율, 동향, 예측(-2026년) Metabolism Drugs Market - Size, Share, Trends, and Forecast till 2026
발행일 : 2018년 07월 페이지 정보 : 영문

United Pompe Foundation(UPF)는 2017년 네덜란드의 폼페병 이환수가 4만명에 1명, 중국 남부 및 대만에서는 5만명에 1명, 아프리카계 미국인에게서는 1만 4,000명에 1명, 코카서스에게서는 10만명에 1명으로 추정하고 있습니다. 폼페병의 이환율 상승, 의약품 연구 개발에 대한 정부 정책 등이 대사 의약품 시장 성장을 지지하고 있습니다.

세계의 대사 의약품(Metabolism Drugs) 시장을 조사했으며, 시장 개요, 치료 종류·용도·유통 채널·지역별 시장 규모 추정과 예측, 시장 성장 촉진요인 및 저해요인 분석, 경쟁 상황, 주요 기업 개요 등의 정보를 제공합니다.

목차

제1장 조사 목적과 가정

  • 조사 목적
  • 가정
  • 약어

제2장 시장 범위

  • 보고서 개요
    • 시장 정의와 범위
  • 주요 요약
    • 시장 정보 : 치료 종류별
    • 시장 정보 : 용도별
    • 시장 정보 : 유통 채널별
    • 시장 정보 : 지역별
  • COM(Coherent Opportunity Map)

제3장 시장 역학, 규제, 시장 동향 분석

  • 시장 역학
    • 성장 촉진요인
    • 성장 저해요인
    • 시장 기회
  • 영향 분석
  • PEST 분석
  • Porter's Five Forces 분석
  • 규제 시나리오

제4장 세계의 대사 의약품 시장 : 치료 종류별

  • 서론
  • 효소보충요법(ERT)
  • 기질감소치료(SRT)
  • 저분자 치료제
  • 기타

제5장 세계의 대사 의약품 시장 : 용도별

  • 서론
  • 당원병
  • 지질대사이상증
  • 아미노산대사이상증
  • 기타

제6장 세계의 대사 의약품 시장 : 유통 경로별

  • 서론
  • 병원 약국
  • 소매 약국
  • 온라인 약국

제7장 세계의 대사 의약품 시장 : 지역별

  • 서론
  • 북미
  • 유럽
  • 아시아태평양
  • 중남미
  • 아프리카
  • 중동

제8장 경쟁 상황

  • 기업 개요
    • Merck & Co., Inc.
    • Novartis AG
    • Amicus Therapeutics
    • AstraZeneca Plc
    • Boehringer Ingelheim
    • Shire Plc
    • Sanofi Genzyme
    • BioMarin Pharmaceutical, Inc.
    • Horizon Pharma Plc
    • GlaxoSmithKline Plc

제9장 부록

  • 참고 문헌
  • 조사 방법
  • Coherent Market Insights 소개
KSM 19.02.28

Increasing prevalence of pompe disease is expected to create lucrative opportunities for pharmaceutical manufacturers to develop and commercialize novel treatments for the disease. For instance, according to United Pompe Foundation (UPF), 2017, the estimated incidence of Pompe disease in Holland is 1 in 40,000, in Southern China and Taiwan: 1 in 50,000 births, African-Americans: 1 in 14,000 births and in Caucasian is 1 in 100,000 population. Initiatives from government organizations for drug research and development is supporting growth of the metabolism drugs market.

For instance, in 2016, the scientist from National Institutes of Health researchers collaborated with National Institute of Neurological Disorders and Stroke (NINDS) and the National Center for Advancing Translational Sciences (NCATS) and researchers identified a new molecule that shows promising approach for treatment of the rare gaucher disease. Moreover, in 2014, European Gaucher Alliance launched Gaucher Awareness Day to spread awareness about this rare disease among the population in Europe.

Market Dynamics

Robust pipeline with various therapies such as enzyme replacement therapy, gene therapy, and small molecule drugs is expected to boost the metabolism drugs market over the forecast period. Increased understanding of diseases and rising number of diagnosed patients are expected to increase the number of patients undergoing treatment.

High prevalence of metabolic diseases is expected to support the growth of the metabolism drugs market. For instance, according to the National Institute of Health (NIH) 2018 report, frequency of hunter syndrome is 1 in 100,000 to 1 in 160,000 in males. Enzyme replacement therapy is expected to show significant growth in the metabolism drugs market over the forecast period.

Key features of the study:

This report provides in-depth analysis of metabolism drugs market and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2018 – 2026), considering 2017as the base year

It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market

This study also provides key insights about market drivers, restraints, opportunities, new application launches or approval, regional outlook, and competitive strategy adopted by the leading players

It profiles leading players in the global metabolism drugs market based on the following parameters – company overview, financial performance, application portfolio, geographical presence, distribution strategies, key developments, and strategies

Key companies covered as a part of this study include Merck & Co., Inc., Novartis AG, Amicus Therapeutics, AstraZeneca Plc, Boehringer Ingelheim, Shire Plc, Sanofi Genzyme, BioMarin Pharmaceutical, Inc., Horizon Pharma Plc, and GlaxoSmithKline Plc.

Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future application launches, technology up-gradation, market expansion, and marketing tactics

The global metabolism drugs market report caters to various stakeholders in this industry including investors, suppliers, application manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the metabolism drugs market

Detailed Segmentation:

  • Global Metabolism Drugs Market, By Therapy Type:
  • Enzyme Replacement Therapy
  • Substrate Reduction Therapy
  • Small Molecule Drugs
  • Others
  • Global Metabolism Drugs Market, By Application:
  • Glycogen Metabolism Disease
  • Lipid Metabolism Disease
  • Amino Acid Metabolism Disease
  • Others
  • Global Metabolism Drugs Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Global Metabolism Drugs Market, By Geography:
  • North America
  • By Therapy Type:
  • Enzyme Replacement Therapy
  • Substrate Reduction Therapy
  • Small Molecule Drugs
  • Others
  • By Application:
  • Glycogen Metabolism Disease
  • Lipid Metabolism Disease
  • Amino Acid Metabolism Disease
  • Others
  • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • By Country:
  • U.S.
  • Canada
  • Europe
  • By Therapy Type:
  • Enzyme Replacement Therapy
  • Substrate Reduction Therapy
  • Small Molecule Drugs
  • Others
  • By Application:
  • Glycogen Metabolism Disease
  • Lipid Metabolism Disease
  • Amino Acid Metabolism Disease
  • Others
  • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • By Country:
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
  • By Therapy Type:
  • Enzyme Replacement Therapy
  • Substrate Reduction Therapy
  • Small Molecule Drugs
  • Others
  • By Application:
  • Glycogen Metabolism Disease
  • Lipid Metabolism Disease
  • Amino Acid Metabolism Disease
  • Others
  • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • By Country:
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Latin America
  • By Therapy Type:
  • Enzyme Replacement Therapy
  • Substrate Reduction Therapy
  • Small Molecule Drugs
  • Others
  • By Application:
  • Glycogen Metabolism Disease
  • Lipid Metabolism Disease
  • Amino Acid Metabolism Disease
  • Others
  • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • By Country:
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East
  • By Therapy Type:
  • Enzyme Replacement Therapy
  • Substrate Reduction Therapy
  • Small Molecule Drugs
  • Others
  • By Application:
  • Glycogen Metabolism Disease
  • Lipid Metabolism Disease
  • Amino Acid Metabolism Disease
  • Others
  • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • By Country:
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
  • By Therapy Type:
  • Enzyme Replacement Therapy
  • Substrate Reduction Therapy
  • Small Molecule Drugs
  • Others
  • By Application:
  • Glycogen Metabolism Disease
  • Lipid Metabolism Disease
  • Amino Acid Metabolism Disease
  • Others
  • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • By Country:
  • Central Africa
  • South Africa
  • North Africa
  • Company Profiles
  • Merck & Co., Inc.*
  • Company Overview
  • Application Portfolio
  • Financial Performance
  • Key Strategies
  • Recent Developments
  • Novartis AG
  • Amicus Therapeutics
  • AstraZeneca Plc
  • Boehringer Ingelheim
  • Shire Plc
  • Sanofi Genzyme
  • BioMarin Pharmaceutical, Inc.
  • Horizon Pharma Plc
  • GlaxoSmithKline Plc
  • “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objective and Assumption

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Therapy Type
    • Market Snippet, By Application
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • PEST Analysis
  • PORTER's Analysis
  • Regulatory Scenario

4. Global Metabolism Drugs Market, By Therapy Type, 2016 - 2026 (US$ Mn)

  • Introduction
    • Market Share Analysis, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, 2017 - 2026
    • Segment Trends
  • Enzyme Replacement Therapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Mn)
  • Substrate Reduction Therapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Mn)
  • Small Molecule Drugs
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Mn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Mn)

5. Global Metabolism Drugs Market, By Application, 2016 - 2026 (US$ Mn)

  • Introduction
    • Market Share Analysis, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, 2017 - 2026
    • Segment Trends
  • Glycogen Metabolism Disease
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Mn)
  • Lipid Metabolism Disease
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Mn)
  • Amino Acid Metabolism Disease
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Mn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Mn)

6. Global Metabolism Drugs Market, By Distribution Channel, 2016 - 2026 (US$ Mn)

  • Introduction
    • Market Share Analysis, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, 2017 - 2026
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Mn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Mn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Mn)

7. Global Metabolism Drugs Market, By Regions, 2016 - 2026 (US$ Mn)

  • Introduction
    • Market Share Analysis, By Region, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, For Regions, 2017-2026
  • North America
    • Market Size and Forecast, By Therapy Type, 2016 - 2026 (US$ Mn)
    • Market Size and Forecast, By Application, 2016 - 2026 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2026 (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2026 (US$ Mn)
    • U.S.
    • Canada
  • Europe
    • Market Size and Forecast, By Therapy Type, 2016 - 2026 (US$ Mn)
    • Market Size and Forecast, By Application, 2016 - 2026 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2026 (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2026 (US$ Mn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Therapy Type, 2016 - 2026 (US$ Mn)
    • Market Size and Forecast, By Application, 2016 - 2026 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2026 (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2026 (US$ Mn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of APAC
  • Latin America
    • Market Size and Forecast, By Therapy Type, 2016 - 2026 (US$ Mn)
    • Market Size and Forecast, By Application, 2016 - 2026 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2026 (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2026 (US$ Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Africa
    • Market Size and Forecast, By Therapy Type, 2016 - 2026 (US$ Mn)
    • Market Size and Forecast, By Application, 2016 - 2026 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2026 (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2026 (US$ Mn)
    • Central Africa
    • South Africa
    • North Africa
  • Middle East
    • Market Size and Forecast, By Therapy Type, 2016 - 2026 (US$ Mn)
    • Market Size and Forecast, By Application, 2016 - 2026 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2026 (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2026 (US$ Mn)
    • GCC
    • Israel
    • Rest of Middle East

8. Competitive Landscape

  • Company Profiles
    • Merck & Co., Inc.
    • Company Overview
    • Application Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Novartis AG
    • Company Overview
    • Application Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Amicus Therapeutics
    • Company Overview
    • Application Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • AstraZeneca Plc
    • Company Overview
    • Application Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Boehringer Ingelheim
    • Company Overview
    • Application Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Shire Plc
    • Company Overview
    • Application Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Sanofi Genzyme
    • Company Overview
    • Application Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • BioMarin Pharmaceutical, Inc.
    • Company Overview
    • Application Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Horizon Pharma Plc
    • Company Overview
    • Application Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • GlaxoSmithKline Plc
    • Company Overview
    • Application Portfolio
    • Key Developments
    • Financial Performance
    • Strategies

9. Section

  • References
  • Research Methodology
  • About Us and Sales Contact
Back to Top
전화 문의
F A Q